The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism?

Clinical Pharmacokinetics

Volumn 41, Issue 4, 2002, Pages 235-253

  Doherty, Margaret M ^a   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C11; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIGOXIN; ERYTHROMYCIN; FELODIPINE; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; NIFEDIPINE; NISOLDIPINE; PHENYTOIN; RIFAMPICIN; SAQUINAVIR; SIMVASTATIN; TACROLIMUS; TERFENADINE; VERAPAMIL;

DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME SUBSTRATE; FIRST PASS EFFECT; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS; REVIEW; SMALL INTESTINE MUCOSA;

EID: 0036093847     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241040-00001     Document Type: Review

References (130)

1. Metabolism of drugs and other xenobiotics in the gut lumen and wall
2. Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine. I. Monooxygenases
3. Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine. II. Conjugases
4. Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man
5. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
6. Differentiation of absorption and first-pass gut metabolism in humans: Studies with cyclosporin
7. First-pass metabolism of midazolam by human intestine
8. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole
9. Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation
10. Intestinal drug absorption and metabolism II: Kinetic aspects of intestinal glucuronide conjugation
11. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP 3A4-medated metabolism
12. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism
13. First-pass effect: Significance of the intestine for absorption and metabolism
14. Metabolism and transport of the macrolide sirolimus in the small intestine
15. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery
16. First-pass metabolism of cyclosporin by the gut
17. The nifedipinerifampicin interaction. Evidence for induction of gut wall metabolism
18. Effect of intestinal and hepatic metabolism on the bioavallability of tacrolimus in rats
19. Metabolism: Scaling-up from in vitro to organ and whole body
20. Prediction of intestinal first-pass effect of phenacetin in the rat from kinetic data-correlation with in vivo data using mucosal blood flow
21. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications
22. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
23. Is the role of the small intestine in first-pass metabolism over-emphasized?
24. The functional morphology of the mucosa of the small intestine
25. Carrier-mediated intestinal absorption of drugs
26. Stool water content and colonic drug absorption: Contrasting the effects of lactulose and codeine
27. Drug transport and targetting: Intestinal transport
28. Improvement of oral bioavailability: Peptidominetics and prodrug strategies
29. Regulation of paracellular absorption of cimetidine and 5-aminosalicylate in rat intestine
30. Clinical pharmacokinetics of cimetidine
31. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
32. Multidrug resistance in human cancer
33. Role of P-glycoprotein and cytochrome P4503A in limiting oral absorption of peptides and peptidomimetic
34. Heterogeneity of cytochrome P450IIIA expression in gut epithelia
35. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
36. Expression of a multi-drug-resistance gene in human tumors and tissues
37. Overlapping substrate specificities and tissue distribution of cytochrome P4503A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
38. A family of drug transporters: The multidrug resistance-associated proteins
39. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
40. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
41. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter
42. Basoleteral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells
43. Expression and immunolocalisation of multidrug resistance protein 2 in rabbit small intestine
44. Restricted intestinal absorption of some beta-lactam antibiotics by an energy-dependent efflux system in rat intestine
45. The physiological function of drug-transporting P-glycoproteins
46. Characterisation of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3)
47. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
48. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
49. Extrahepatic metabolism of drugs in humans
50. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
51. Comparisons of catalytic selectivity of cytochrome P450 subfamily from different species
52. Induction of cytochrome P4501A genes (CYP1A) by omeprazole in the human alimentary tract
53. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
54. Cytochromes P450 in the intestinal mucosa of man
55. Comparative studies of drug-metabolizing enzymes in dog, monkey and human small intestines, and in Caco-2 cells
56. The role of xenobiotic metabolising enzymes in arylamine toxicity and carcinogenesis: Functional and localizational studies
57. Characterisation of human small intestinal cytochromes P-450
58. Cytochrome P4501A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole
59. Cytochrome P450 isoenzymes, epoxide hydrolase and gluthathione transferases in rat and human hepatic and extrahepatic tissues
60. Effects of the antifungal agents on oxidative drug metabolism
61. Isolation and characterization of human liver cytochrome P4502C19: Correlation between 2C19 and (S)-mephenytoin 4-hydroxylation
62. Identification of rifampicin-inducible P450IIIA (CYP3A4) in human small bowel enterocytes
63. Pharmacokinetics. The dynamics of drug absorption, disposition and elimination
64. Interpatient heterogeneity in expression of CYP 3A4 and CYP 3A5 in small bowel: Lack of prediction by the erythromycin breath test
65. Sequences of intestinal and hepatic and cytochrome P4503A4 cDNAs are identical
66. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
67. (+) and (-) Terbutaline are sulphated at a higher rate in human intestine than in the liver
68. Induction of UDP-glucuronosyltransferase by the flavinoids chrysin and quercetin in caco-2 cells
69. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes
70. Studies on absorption and excretion of drugs. IV Absorption of various sulfonamides from the rat small intestine by the perfusion method in vivo
71. Transport of theophylline from blood to the intestinal lumen following IV administration to rats
72. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in caco-2 cells: Interaction between the two biochemical barriers to intestinal transport
73. First-pass accumulation of salicylic acid in gut tissue after absorption in anesthetized rat
74. Carrier-mediated approaches for oral drug delivery
75. The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: A mechanism contributing to poor oral absorption
76. First-pass metabolism of gentisamide: Influence of intestinal metabolism on hepatic formation of conjugates. Studies in the once-through vascularly perfused rat intestine-liver preparation
77. Uptake, 3-, and 6-glucuronidation of morphine in isolated cells from stomach, intestine, colon, and liver of the guinea pig
78. Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters
79. Propranolol: Pooled Michaelis-Menten parameters and the effect of input rate on bioavailability
80. Intestinal blood flow
81. Effects of vasoactive intestinal polypeptide on intestinal absorption and blood flow
82. Mucosal blood circulation and its influence on passive absorption in the small intestine: An experimental study in the cat
83. Intestinal villus blood flow measured with carbon monoxide and microspheres
84. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism
85. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The effect of lipids and pH
86. Jejunal absorption and metabolism of R/S-verapamil in humans
87. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies
88. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
89. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
90. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine
91. Cyclosporin-erythromycin interaction in renal transplant patients
92. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
93. Acute heart transplant rejection due to Saint John's wort
94. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
95. Indinavir concentrations and St John's wort
96. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin
97. On the interaction between phenytoin and digoxin
98. Pharmacokinetic interaction of digoxin with a herbal extract from St John's wort
99. Interaction between grapefruit juice and midazolam in humans
100. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
101. Interaction of citrus juices with felodipine and nifedipine
102. Erythromycin-felodipine interaction: Magnitude, mechanism and comparison with grapefruit juice
103. Effects of grapefruit juice ingestion -pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men
104. Itraconazole greatly increases plasma concentrations and effects of felodipine
105. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics
106. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride
107. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram
108. Torsades de pointes after treatment with terfenadine and ketoconazole
109. Torsades de pointes induced by erythromycin and terfenadine
110. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
111. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
112. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
113. Grapefruit juice increases serum concentrations of lovastatin and lovastatin acid
114. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
115. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
116. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin
117. Influence of food intake on presystemic clearance of drugs
118. Effect of food on clinical pharmacokinetics
119. 6′7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein
120. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers
121. Influence of grapefruit juice on cisapride pharmacokinetics
122. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects
123. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexodenaine
124. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
125. A phase II/pharmacokinetic analysis of high-dose progesterone in combination with paclitaxel
126. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma: Drug-drug interactions with protease inhibitors and nonnucleoside reverse transcriptase inhibitor: A case report study
127. Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans
128. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa
129. Clinical pharmacokinetic considerations in the elderly
130. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans